U.S. STOCKS ON THE MOVE-OneStream, FuelCell Energy, Alibaba
Psychedelic drug developers rise as RFK Jr picked for top US health agency role
Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role
Brief: GH Research Appoints Velichka Valcheva As CEO
Brief: GH Research Announces Grant of European Patent Covering All Mebufotenin (5-MeO-DMT) And Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
Brief: GH Research PLC Q2 EPS USD -0.15
Brief: GH Research PLC Posts Qtrly Net Loss Of $10.9 Mln
Brief: Gh Research PLC Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Brief: GH Research Initiates Mid-stage Study In Treatment-Resistant Depression
Brief: GH Research Provides Business Updates
Brief: GH Research Says Cash Was $265.4 Mln As Of June 30, 2022
Brief: Gh Research Q1 Loss Of 11 Cents Per Share
GH Research slips after brokerage cuts PT on possible delay in Europe drug launch
Brief: GH Research Reports Full Year 2021 Financial Results
GH Research soars as depression treatment succeeds in study
Brief: GH Research Reports Third Quarter 2021 Financial Results
Brief: GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
Brief: GH Research Reports Q2 Loss Per Share Of $0.053
NASDAQ RESUMED AT 10:23 AM